Manganese and Platinum Driven Oxidative and Nitrosative Stress in Oxaliplatin‐Associated CIPN with Special Reference to Ca4Mn(DPDP)5, MnDPDP and DPDP

preprint OA: closed CC-BY-4.0
🔓 Open OA copy View at publisher
AI-generated summary by claude@2026-07, 2026-07-15

Pt2+ chelation and elimination by DPDP, not Mn2+ from MnDPDP, is responsible for oxaliplatin-associated neurotoxicity protection.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

There is little doubt that the efficacy of MnDPDP and its therapeutic improved counterpart Ca4Mn(DPDP)5 mainly depends on their MnSOD-mimetic activity when it comes to their potential use as rescue medicines, during e.g., acute myocardial infarction. However, pharmacokinetic considerations suggest that the efficacy of MnDPDP on Pt2+-associated neurotoxicity depends on another action of this drug. Electron Paramagnetic Resonance (EPR) studies have demonstrated that Pt2+ outcompetes Mn2+ and endogenous Zn2+ from binding to fodipir (DPDP), and hence suggest that the previously reported CIPN protective efficacy of MnDPDP is a result of chelation and elimination of Pt2+ by DPDP, which in turn suggests that Mn2+ is unnecessary for efficacy when it comes to oxaliplatin-associated CIPN.

My notes (saved in your browser only)

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. This is a recent paper (2024) — citers typically take a year or two to land, and the OpenAlex reference graph may still be filling in.

Source provenance

europepmc
last seen: 2026-05-20T01:45:00.602351+00:00
unpaywall
last seen: 2026-05-26T02:00:01.498150+00:00
License: CC-BY-4.0